A Growing Global Immune Cancer Medicine Market
KSA Immune Cancer Medicines Market
The current market for precision immune medicines is expected to grow from SAR 6bln to over SAR 13.9bln by 2030, representing a CAGR of 8.6%.
Global Immune Cancer Medicines Market
As personalised, precision medicine demonstrates superior control and relief from disease across many disease areas, the precision immune cancer medicines market globally has surged, with a CAGR of 16.5% delivering a global market value of SAR 412bln by 2032.
Access to a Global Export Market
IO:GULFs planned pipeline of medicines will make Saudi Arabia a major exporter of next generation cancer medicines. The advanced features of TCR bispecifics open up global patient populations by taking advantage of key genetic similarities during medicines development.
Manufacturing, Technology and Academic Opportunities
The phenomenal growth in the precision immune cancer medicines market gives rise to a vast array of opportunities. Developing, growing and scaling key technology transfer and manufacturing partnerships in Saudi Arabia at a global scale whilst bolstering the strength of the Saudi economy with local joint academic and commercial partnerships and ventures, integrating Saudi graduate talent into this profitable industry and maximising the benefits to Saudi society from the ground up.
IO:GULF Supporting the Saudi Market
In alignment with the Vision 2030 and National Biotechnology Strategies, IO:GULFs business model is integrally linked to delivering the full social and financial benefits of the global cancer immune medicines market to the Kingdom of Saudi Arabia. Promoting Saudi interests, talents and achievements on the global stage.